FDA Launches ICH M15 MIDD Guidance, Reshaping IND Submission Strategy for Sponsors

Quantitative modeling is no longer a supplementary consideration in drug development packages, FDA's release of ICH M15 General Principles for Model-Informed Drug Development guidance in June 2026 signals a structural shift in how sponsors are expected to document and justify MIDD approaches within IND submissions and meeting requests. Regulatory affairs leads preparing packages under 21 CFR Part 312 should treat alignment with ICH M15 as a baseline expectation, not an optional enhancement.

The guidance arrives within the framework of FDA's MIDD Paired Meeting Program, a PDUFA VII performance commitment running through fiscal year 2027 under CDER and CBER. The program accepts one to two paired-meeting requests per quarter, with each accepted request yielding an initial and follow-up meeting on the same development issues. Priority is given to submissions addressing dose selection, clinical trial simulation, and predictive or mechanistic safety evaluation using systems pharmacology or mechanistic models.

ICH M15 is designed to support a multidisciplinary understanding of MIDD across exposure-based, biological, and statistical modeling disciplines. The guidance covers MIDD planning, model evaluation, and evidence documentation, three areas where submission packages have historically varied in rigor. FDA's explicit recommendation to use ICH M15 when preparing meeting requests effectively raises the documentation standard sponsors will be measured against during regulatory review.

Eligibility for the paired meeting program requires an active IND or Pre-IND number. Consortia and software or device developers may participate only in partnership with a drug development company. Notably, the program excludes statistical designs involving complex adaptive features, Bayesian methods, or computer simulation-dependent confirmatory trial designs, a boundary that regulatory teams should map carefully against their existing development programs before submitting.

For QA directors, the relevance centers on evidence documentation: ICH M15's recommendations on model evaluation introduce a traceable evidence chain that intersects with ICH Q10 pharmaceutical quality system principles, particularly around knowledge management and continual improvement of development-stage models. Teams integrating MIDD outputs into process validation or dose-bridging rationales should review internal documentation practices against the new standard before the next quarterly submission window.

Sponsors targeting the next quarterly deadline can direct meeting requests to [email protected]; the measurable outcome to track is whether submitted packages demonstrably reflect ICH M15's planning and evidence documentation principles, as that alignment is now the stated basis for FDA's review of MIDD meeting requests.

Source: FDA CDER via FDA.gov What's New: Drugs RSS Feed, July 7, 2026.